Archive: November 2023

Overcoming the Hurdles: Surmounting Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer

Abstract: Colorectal cancer is the third most prevalent cancer type in the United States, with an alarming incidence and mortality rate, especially among individuals younger than […]

Surgical Resection Criteria and Neoadjuvant Therapies for Intrahepatic Cholangiocarcinoma

Abstract: The staging of intrahepatic cholangiocarcinoma (ICC) is complex, and there is no consensus among international cancer groups on how to most appropriately select candidates with […]

The Latest Breakthrough in Breast Cancer Treatment

H&O  Can you go into the details of elacestrant’s US Food and Drug Administration (FDA) approval? SMT  Elacestrant (Orserdu, Stemline) is an oral selective estrogen receptor […]

Treatment of Less-Common Complications of Sickle Cell Disease

H&O  What are the most common complications of sickle cell disease? UO  Sickle cell disease is associated with several complications, both acute and chronic. The most […]

Tips on Choosing a CAR T-Cell Therapy in DLBCL

H&O  What chimeric antigen receptor (CAR) T-cell therapies are approved for diffuse large B-cell lymphoma (DLBCL), and how do they differ? JA  There are 3 approved […]

Are Vaccines Making a Comeback in Melanoma?

H&O  What vaccines are approved for use in melanoma? JW  We do not have any true vaccines that are approved and used for cancer at this […]

Letter From the Editor: My Ongoing Debate

Some would argue that the first tenet of chronic lymphocytic leukemia (CLL) is to “watch and wait” until patients have an indication for treatment. This tenet […]

Back to Archive